All In Biotech

Drug Trial Radar · NCT01533532

A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)

A Multicenter, Randomized, Placebo-controlled, Double-blind Phase II Study of KLH-2109 in Patients With Endometriosis(2)

Last checked: Nov 19, 2026Latest source record: May 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Not stated

Primary completion

Not stated

Sponsor

Sponsor type
Industry
First posted
Feb 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.

Conditions

  • Endometriosis

Interventions

  • KLH-2109Drug

  • KLH-2109Drug

  • KLH-2109Drug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The severity score of the pelvic painTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Japan

    Tokyo and Other Japanese City, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.